Diversified Trust Co Has $4.56 Million Stake in Bristol Myers Squibb Company $BMY

Diversified Trust Co increased its stake in Bristol Myers Squibb Company (NYSE:BMY) by 56.0% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 101,051 shares of the biopharmaceutical company’s stock after purchasing an additional 36,288 shares during the quarter. Diversified Trust Co’s holdings in Bristol Myers Squibb were worth $4,557,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Brighton Jones LLC lifted its position in Bristol Myers Squibb by 33.4% during the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after acquiring an additional 4,935 shares during the last quarter. Jump Financial LLC bought a new position in shares of Bristol Myers Squibb in the first quarter worth about $438,000. Baird Financial Group Inc. lifted its position in shares of Bristol Myers Squibb by 5.2% during the 1st quarter. Baird Financial Group Inc. now owns 532,879 shares of the biopharmaceutical company’s stock worth $32,500,000 after purchasing an additional 26,478 shares during the last quarter. Graham Capital Management L.P. bought a new stake in Bristol Myers Squibb during the 1st quarter valued at approximately $568,000. Finally, Beck Mack & Oliver LLC acquired a new stake in Bristol Myers Squibb in the 1st quarter valued at approximately $213,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on BMY shares. Sanford C. Bernstein reiterated a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, November 3rd. Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. HSBC restated a “hold” rating and issued a $53.00 price target on shares of Bristol Myers Squibb in a research report on Wednesday, December 10th. Guggenheim reaffirmed a “buy” rating on shares of Bristol Myers Squibb in a research report on Tuesday, December 23rd. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Bristol Myers Squibb in a research report on Tuesday, October 14th. Six equities research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $54.62.

Bristol Myers Squibb Stock Performance

NYSE:BMY opened at $54.15 on Tuesday. The firm has a market capitalization of $110.23 billion, a PE ratio of 18.29, a price-to-earnings-growth ratio of 8.36 and a beta of 0.29. The company has a quick ratio of 1.17, a current ratio of 1.27 and a debt-to-equity ratio of 2.39. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $63.33. The firm has a 50-day moving average price of $49.04 and a 200 day moving average price of $47.35.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share for the quarter, beating analysts’ consensus estimates of $1.52 by $0.11. Bristol Myers Squibb had a return on equity of 76.53% and a net margin of 12.57%.The company had revenue of $12.22 billion for the quarter, compared to the consensus estimate of $11.75 billion. During the same period in the previous year, the business earned $1.80 earnings per share. The company’s quarterly revenue was up 2.8% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Research analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd will be paid a dividend of $0.63 per share. This is an increase from Bristol Myers Squibb’s previous quarterly dividend of $0.62. This represents a $2.52 annualized dividend and a yield of 4.7%. The ex-dividend date is Friday, January 2nd. Bristol Myers Squibb’s dividend payout ratio is currently 83.78%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.